Subscribe for the latest consumer trends, trade news, nutrition science and regulatory updates in the supplement industry!
Join 37,000+ members. Yes, it's completely free.
Next Pharmaceuticals
January 15, 2007
1 Min Read
CARLSBAD, Calif.—Next Pharmaceuticals concluded a successful trial of its new patented heart health ingredient, Flavoxine™. After intervention, subjects’ levels of high-density lipoprotein (HDL, or “good”) cholesterol were increased. Flavoxine™ is a blend of two proprietary extracts from Phellodendron amurense and orange peel containing polymethoxylated flavones. Next Pharmaceuticals (www.nextpharmaceuticals.com) said the trial also found Flavoxine significantly lowered blood pressure and fasting blood glucose in the patient population.
You May Also Like